189 related articles for article (PubMed ID: 32815181)
41. Aggregate Removal Nanofiltration of Human Serum Albumin Solution Using Nanocellulose-Based Filter Paper.
Wu L; Mantas A; Gustafsson S; Manukyan L; Mihranyan A
Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32668723
[TBL] [Abstract][Full Text] [Related]
42. Use of a noninfectious surrogate to predict minute virus of mice removal during nanofiltration.
Cetlin D; Pallansch M; Fulton C; Vyas E; Shah A; Sohka T; Dhar A; Pallansch L; Strauss D
Biotechnol Prog; 2018 Sep; 34(5):1213-1220. PubMed ID: 30194917
[TBL] [Abstract][Full Text] [Related]
43. Pathogen safety of Beriate®.
Gröner A
Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
[TBL] [Abstract][Full Text] [Related]
44. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.
Cai K; Gröner A; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gajardo R; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Lee DC; Moscardini M; Pölsler G; Roth NJ
Transfusion; 2013 Sep; 53(9):1894-905. PubMed ID: 23252676
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products.
Chandra S; Groener A; Feldman F
Thromb Res; 2002 Mar; 105(5):391-400. PubMed ID: 12062540
[TBL] [Abstract][Full Text] [Related]
46. Characterization of Thrombate III®, a pasteurized and nanofiltered therapeutic human antithrombin concentrate.
Cai K; Osheroff WP; Buczynski G; Hotta J; Lang J; Elliott E; Lee DC; Roth NJ
Biologicals; 2014 May; 42(3):133-8. PubMed ID: 24477183
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
48. Assessment of the efficacy of membrane filtration processes to remove human enteric viruses and the suitability of bacteriophages and a plant virus as surrogates for those viruses.
Shirasaki N; Matsushita T; Matsui Y; Murai K
Water Res; 2017 May; 115():29-39. PubMed ID: 28259077
[TBL] [Abstract][Full Text] [Related]
49. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
Caballero S; Nieto S; Gajardo R; Jorquera JI
Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
[TBL] [Abstract][Full Text] [Related]
50. Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products.
Yue C; Teitz S; Miyabashi T; Boller K; Lewis-Ximenez LL; Baylis SA; Blümel J
Viruses; 2019 Mar; 11(3):. PubMed ID: 30866548
[TBL] [Abstract][Full Text] [Related]
51. Clearance of dengue virus in the plasma-derived therapeutic proteins.
Xie YW; Chan PK; Szeto CK; Kwok SY; Chu IM; Chu SS; Cheung JL; Wong SW; Ali MB; Wong BL
Transfusion; 2008 Jul; 48(7):1342-7. PubMed ID: 18315529
[TBL] [Abstract][Full Text] [Related]
52. Quantitative PCR evaluation of parvovirus B19 removal via nanofiltration.
Ideno S; Takahashi K; Yusa K; Sakai K
J Virol Methods; 2020 Jan; 275():113755. PubMed ID: 31647943
[TBL] [Abstract][Full Text] [Related]
53. Chromatographic removal of viruses from plasma derivatives.
Burnouf T
Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
[TBL] [Abstract][Full Text] [Related]
54. Nanofiltration of single plasma donations: feasibility study.
Burnouf T; Radosevich M; El-Ekiaby M; Satoh S; Sato T; Amin SN; Savidge GF; Goubran HA
Vox Sang; 2003 Feb; 84(2):111-9. PubMed ID: 12609017
[TBL] [Abstract][Full Text] [Related]
55. Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance.
Morrica A; Nardini C; Falbo A; Bailey AC; Bucci E
Biologicals; 2003 Sep; 31(3):165-73. PubMed ID: 12935804
[TBL] [Abstract][Full Text] [Related]
56. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
57. Safety issues for plasma derivatives and benefit from NAT testing.
Willkommen H; Schmidt I; Löwer J
Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
[TBL] [Abstract][Full Text] [Related]
58. Meeting report--workshop on virus removal by filtration: trends and new developments.
Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Kreil TR; Robertson JS; Ruffing M; Ruiz S
PDA J Pharm Sci Technol; 2013; 67(2):98-104. PubMed ID: 23569071
[TBL] [Abstract][Full Text] [Related]
59. Improved virus safety and purity of a chromatographically produced factor IX concentrate by nanofiltration.
Hoffer L; Schwinn H; Biesert L; Josic D
J Chromatogr B Biomed Appl; 1995 Jul; 669(2):187-96. PubMed ID: 7581895
[TBL] [Abstract][Full Text] [Related]
60. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
